Vertex Pharmaceuticals chief Reshma Kewalramani said AI could reduce the time spent on drug-approval paperwork from months to ...

Vertex Energy (VTNR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is trading near a record high after climbing about 20% so far this year, and delivering a triple-digit gain over three years. So, you may be a bit hesitant about ...

Loomis Sayles, an investment management company, released its “Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter, the fund returned ...

Days before three scientists at Boston-based Vertex Pharmaceuticals will share a $3 million prize for revolutionizing the treatment of cystic fibrosis, the award — sometimes called the Oscars of ...

In its upcoming report, Vertex Pharmaceuticals (VRTX) is predicted by Wall Street analysts to post quarterly earnings of $4.22 per share, reflecting a decline of 11.3% compared to the same period last ...

Vertex has built a billion-dollar business thanks to its expertise in treating cystic fibrosis. The biotech stock is cheaper today than it was earlier this year in relation to expected earnings. But ...

Vertex Pharmaceuticals has built a billion-dollar cystic fibrosis business over time. But the company today may be preparing for a new era of growth, thanks to the strength of its pipeline. Vertex ...